DXCM Stock Recent News
DXCM LATEST HEADLINES
Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies.
DXCM continues to raise investor optimism due to its strong product portfolio.
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO.
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX.
DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, gross margin declines and cost pressures present significant downside risks. My updated DCF analysis yields a price target of $92.90 for DXCM stock, only a 9% upside from current prices, reducing the margin of safety.
DexCom, Inc. NASDAQ: DXCM has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that underscore its sustained momentum. The company's performance, driven by strong product demand, successful innovation, and strategic market access expansion, strongly supports an ambitious trajectory for the remainder of 2025, indicating a clear path towards further solidifying its leadership in diabetes technology.
The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month.